Loading…
Loading…
X-FAB is a pure-play specialty semiconductor foundry — it fabricates chips for fabless customers but does not sell its own branded products.
This dossier IS the ultimate parent (X-Fab Silicon Foundries SE, LEI 5493003UDPENPUQBJH65 via GLEIF; GLEIF reports no further parent). No single holder has a majority or controls in concert: the 2023-11-14 FSMA notification explicitly records the prior Duchatelet/De Winter-Chombar/Sarawak concert-party agreement as TERMINATED, so despite the three blocks above summing to ~63%, none acts jointly with another — remaining ~37% is free float. GLEIF separately shows two DE subsidiaries (X-FAB Global Services GmbH, X-FAB Semiconductor Foundries GmbH) with this entity as direct/ultimate parent, and an FR entity (X-FAB FRANCE, LEI 894500DQKBDQEYD66N56) with no parent relationship filed — consistent with one group dossier covering the whole footprint.
Named counterparties identified by open-source research and written only where a primary source states the relationship — never inferred from sector or co-mention. 1 supplier. This is a partial view: it covers the relationships we could evidence, not the company's full supply base.
IHP licensed its SiGe BiCMOS process technology to X-FAB, which volume-manufactures the resulting XR013 130nm platform at its Corbeil-Essonnes, France fab. Named and sourced in X-FAB's own press release, already cited in this dossier's Sources list for the germanium/copper exposure claims.
Scope. Absence of a counterparty here is not evidence that none exists — most commercial sourcing is confidential and never becomes public. Rows without a share figure mean no share was disclosed, not that the relationship is small.
Another tracked dossier names this company as a counterparty in its own sourced disclosure — this platform never wrote these rows on this company's own page, they are read here inverted from the dossier that disclosed them. This is a partial view: 990 additional named-counterparty rows across the corpus could not be matched to a tracked dossier by name at all (mostly non-Latin legal names), so the true count is higher than what renders here.
Melexis's own Belgian Code art. 7:97 related-party-transaction disclosure covers its wafer long-term agreements with X-FAB: 2023-2025 LTA for 350nm/180nm nodes and a 2024-2027 LTA for 110nm, with an operational capacity-reservation prepayment of ~EUR 189.2 million. X-FAB's share of revenue from Melexis is not filed here: no primary X-FAB figure was re-checked (secondary write-ups conflict, 40% vs 45% for FY2023).
Scope. This section is inverted evidence: each linked dossier wrote the original row about itself, describing its own relationship to this company. It is never a claim this company itself disclosed. Absence here is not evidence of no relationship — most of the corpus has no named-counterparty block at all yet.
Every exposure is read as a buyer dependency; the top 3 are its binding chokepoints.
As a buyer, policy pressure across its consumed materials is rising.
Descriptive trend in official policy actions on this company’s materials — a policy-pressure trend, not a price or trading signal. No forward probability is implied. Direction is measured on actions we have discovered, and discovery lags events: where the recent window is too thin to support a calm reading, the row says coverage-limited instead of easing.
No actions in the register have named or swept this company in the last 24 months.